一种针对慢性乙型肝炎的肠肝轴的新疗法:乌尔苏多氧胆酸加Bifidobacterium
Zhen Xun1,2, Xiaobao Yao1, Caorui Lin3,1
1Department of Laboratory Medicine, Fujian Key Laboratory of Laboratory Medicine, Gene Diagnosis Research Center, Fujian Clinical Research Center for Clinical Immunology Laboratory Test, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian Province, China.
结合ursodeoxycholic acid (UDCA) 和Bifidobacterium显示出治疗慢性乙型肝炎 (CHB) 的前景. 这种肠肝轴疗法增强了免疫细胞功能,控制了HBV病毒载量,提供了潜在的新治疗策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 肠肝轴是肝脏疾病治疗的关键目标.
- 慢性乙型肝炎 (CHB) 涉及肠道微生物群和胆酸 (BA) 代谢之间的复杂相互作用.
- Ursodeoxycholic 酸 (UDCA) 和 Bifidobacterium 在 CHB 中正在研究它们的治疗潜力.
研究的目的:
- 为了评估UDCA和Bifidobacterium结合治疗CHB的疗效.
- 评估这种联合治疗对肠道微生物群-胆酸轴和CHB患者免疫反应的影响.
主要方法:
- 在CHB患者和健康对照中分析了血清BA概况和肠道微生物群组成.
- 临床前模型和为期2个月的临床试验 (n=22) 评估了UDCA和Bifidobacterium单疗法与组合疗法.
- 测量了免疫细胞功能 (NK,CD8+ T细胞) 和病毒标记物.
主要成果:
- 在CHB患者中,UDCA显著降低,并显示出抗HBV效应.
- 在CHB患者中,Bifidobacterium的丰富性降低了,并且在体内表现出抗HBV活性.
- 组合疗法显著降低了HBV DNA,基因前RNA和HBsAg,同时增强了CD8+ T/NK细胞功能.
结论:
- 联合UDCA和Bifidobacterium治疗有效控制HBV.
- 这种组合疗法促进了CD8+ T细胞和NK细胞的功能.
- 用UDCA和Bifidobacterium准肠道微生物群-胆酸轴是对CHB的一个有希望的辅助疗法.
更多相关视频
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
